Background: Women at high risk for breast cancer and women at average risk have different pretest probabilities. Probably benign lesions on screening ultrasound (US) should be assessed and managed differently for these two risk groups. Purpose: To evaluate the effectiveness of short-term follow-up for probably benign lesions on screening US in women at average risk for breast cancer with dense breasts. Material and Methods: A total of 445 women at average risk for breast cancer with probably benign lesions on screening US, dense breasts, and negative or benign mammography results were included. Women were classified into the six-month group (n ¼ 345) or 12-month group (n ¼ 100) according to when the first follow-up was performed (3-9 months or 9-15 months). The cancer detection rate, frequencies of newly developed lesions and progressed lesions, and biopsy rate were compared. Results: There were no malignancies from three to 15 months. Three cancers newly developed after 15 months. One was a 3-mm ductal carcinoma in situ and two were 10-mm and 18-mm invasive ductal carcinoma without lymph node metastasis. The frequency of newly developed lesions and progressed lesions and biopsy rate were not significantly different between the six-month and 12-month groups (P ¼ 0.320, 0.621, and >0.999). Conclusion: A follow-up at 12 months can be considered for probably benign lesions on screening US in women at average risk for breast cancer with dense breasts. However, a large series prospective study is needed before clinical application.
Introduction
The number of screening ultrasounds (US) being performed has increased continuously since legislation passed that requires physicians to directly notify women of their breast density after screening mammography and to inform those with dense breasts of other supplementary screening tools such as US or magnetic resonance imaging (MRI) (1) (2) (3) . Screening US in women with dense breasts can detect an additional 1.8-4.6 cancers per 1000 women regardless of breast cancer risk (1) (2) (3) (4) (5) (6) (7) (8) (9) . Cancers detected on US only are clinically significant, because 50-100% of these cancers are predictive value due to a high short-term follow-up rate and benign biopsy rate (4) (5) (6) 8) . In screening US, the reported frequencies of probably benign lesions are in the range of 8.6-41.4% (4) (5) (6) 8, 12, 13) . Consequently, many efforts have been made to reduce the short-term follow-up rate of screening US in women at high risk for breast cancer (6, 12, 14) . Women at high risk for breast cancer and women at average risk naturally have different pretest probabilities for breast cancer (9, 12) . Thus, probably benign lesions on screening US should be assessed and managed differently for these two risk groups. A recent study found routine screening US to be preferable over short-term follow-up for probably benign lesions in women at average risk for breast cancer (13) . However, in that study, newly developed lesions on follow-up US were not evaluated and the cancer detection rate, the frequencies of newly developed lesions and progressed lesions, and the biopsy rate were not compared directly between six and 12 months of follow-up.
Therefore, we evaluated the effectiveness of shortterm follow-up at six months for probably benign lesions on screening US in women at average risk by comparing the cancer detection rate, the frequencies of newly developed lesions and progressed lesions, and the biopsy rate between six and 12 months of follow-up.
Material and Methods

Study population
The Institutional Review Board approved this retrospective study and informed consent was waived.
From March 2010 to February 2013, 31,373 bilateral mammography examinations were performed. Women with the following criteria were selected: women with screening mammography; with heterogeneously or extremely dense breasts; with negative or benign mammography results; with initial screening US within three months after screening mammography; and with no known risk factors for breast cancer other than dense breasts. Of 3523 women with the above mentioned criteria, 820 women (23.2%) had category 3 assessments on initial screening US. Of these 820 women, 307 without any follow-up at our institution and 68 with the first follow-up after 15 months were excluded. A total of 445 women who underwent a first follow-up US 3-15 months after their initial US were included in our study. The mean age was 48.2 AE 8.1 years (age range ¼ 22-73 years) and the mean follow-up interval from initial US to last follow-up US was 24.5 AE 15.9 months (range ¼ 3.2-60.3 months). All 445 women were already included in the previous study, which was about the application of the downgrade criteria for supplementary screening US in women with negative mammography and dense breast (15) .
Mammography and US examinations
Mammography was performed using dedicated equipment: the Lorad/Hologic Selenia full-field digital mammography system (Lorad/Hologic, Danbury, CT, USA) and the General Electric Senographe digital mammography system (GE Healthcare, Milwaukee, WI, USA). Craniocaudal and mediolateral oblique views were routinely obtained in screening settings. Additional views were considered for diagnostic mammography and were obtained when needed. Mammography was interpreted by one of seven dedicated breast imaging radiologists with a range of 1-15 years of experience in breast imaging (including authors HJM, MJK, and EKK). Breast densities were classified into four grades according to the American College of Radiology (ACR) Breast Imaging and Reporting System (BI-RADS) (16, 17) . The final assessments, BI-RADS categories of screening mammography, were assessed based on ACR BI-RADS (16) (17) (18) .
All screening US examinations were performed by one of seven radiologists (including authors HJM, MJK, and EKK) with US machines (iU22 or HDI 5000, Philips-Advanced Technology Laboratories, Bothell, WA, USA; Logic 9, GE Healthcare) and 5-12 or 7-12 MHz linear array transducers. Before performing screening US, each woman's mammography results and clinical information were made available to the performing and interpreting radiologists. Screening US included bilateral whole breasts and axillary areas. One final assessment was given for the highest category if multiple lesions were found on US. BI-RADS category 3, the probably benign finding of screening US, was assessed according to the guidelines of previous studies and ACR BI-RADS (4, 16, 18) . Solid masses with oval, well-circumscribed, and parallel orientation with no posterior acoustic features or minimal posterior enhancement, complicated cysts, and clustered microcysts were classified as probably benign (4,16).
Follow-up and management
Short-term follow-up at six months with US was recommended and performed for probably benign lesions. Afterwards, follow-up US and mammography were performed at 12 and 24 months. If women or their clinicians chose to undergo biopsy for category 3 lesions, a biopsy was performed under US guidance. If a category 3 lesion showed progression on follow-up US, the lesion underwent biopsy (19) . During follow-up, newly developed probably benign lesions were biopsied according to the preferences of the clinicians and patients.
Data and statistical analysis
Women with the first follow-up performed 3-9 months after initial US were classified into the six-month group and women with the first follow-up performed 9-15 months after initial US were classified into the 12-month group. Of 445 women, 345 were classified into the six-month group and 100 were classified into the 12-month group. Cancer detection was defined as cancer detected on the first follow-up US. The frequencies of progressed lesions and the frequencies of newly developed lesions in the six-month and 12-month groups were defined by progression and new appearance of lesions observed at 3-9 months and 9-15 months, respectively. Among the lesions that were discovered during follow-up, lesions assessed as category 3 or higher were considered newly developed lesions. Simple cysts of benign findings were not considered newly developed lesions. Progression was recorded based on the original radiological report. Biopsies, which were performed for newly developed or progressed lesions during the corresponding periods of the six-month and 12-month groups, were analyzed. The cancer detection rate, progression rate, newly developed lesion rate, and biopsy rate were compared between the two groups using Fisher's exact test or the Chi-square test. Age was compared between the two groups with the independent t-test. Statistical analysis was performed using SPSS Õ statistical software version 20.0 (SPSS Inc., Chicago, IL, USA). A two-sided P value <0.05 was considered to indicate statistical significance.
Results
None of the 445 women had any malignancies discovered during follow-up at 3-15 months. Three women, all included in the six-month group, had cancers and all of these cancers were newly developed lesions found after 15 months (Table 1) . The cancers were a 3-mm low-grade ductal carcinoma in situ found at 15 months, an 18-mm invasive ductal carcinoma without lymph node metastasis found at 32.2 months, and a 10-mm invasive ductal carcinoma without lymph node metastasis found at 21.6 months.
Among 345 women in the six-month group, 125 underwent a second follow-up US at 9-15 months and 122 underwent a second follow-up US after 15 months. Sixty-three had newly developed lesions discovered only at the first follow-up, 18 at both the first and second follow-ups performed at 9-15 months, and 34 only at the second follow-up. The data from the first follow-up were included for analysis. Of 81 women with newly developed lesions at the first follow-up, 76 (93.8%, 76/81) had probably benign lesions and five (6.2%, 5/81) had category 4a lesions. The biopsy results were fibrocystic change (n ¼ 2), fibroadenoma (n ¼ 2), and stromal fibrosis (n ¼ 1). Four lesions (1.2%) showed progression at the first follow-up and the biopsy results were fibroadenoma (n ¼ 2), fibrocystic change (n ¼ 1), and ductal epithelial hyperplasia (n ¼ 1). Of 12 biopsied lesions (3.2%), three were newly developed probably benign lesions and the three biopsy results were fibroadenoma, sclerosing adenosis, and fibrocystic change.
Among 100 women in the 12 months group, 66 underwent a second follow-up US after 15 months. Of 29 women (29%, 29/100) with newly developed lesions discovered at the first follow-up, 28 (96.6%, 28/29) had probably benign lesions and one (3.4%, 1/29) had a category 4a lesion. The biopsy result of the newly developed lesion was fibroadenoma. Two lesions (2%) showed progression at the first follow-up and were confirmed as fibroadenoma through biopsy. Biopsies were performed on three lesions (3%).
The mean age was not significantly different between the six-month and 12-month groups (P ¼ 0.916) ( Table 2 ). Newly developed lesions were more frequently seen in the 12-month group than the six-month group, but the difference was not statistically significant (P ¼ 0.320). The frequencies of progressed lesions and biopsy rates were not significantly different (P ¼ 0.621 and >0.999).
Discussion
We evaluated the effectiveness of short-term follow-up at six months for probably benign lesions on screening US. Probably benign lesions on screening US in women at average risk for breast cancer with dense breasts and negative or benign mammography results can be followed up at 12 months instead of six months due to the 0% malignancy rate of the six-month follow-up. All three malignancies of newly developed lesions in our study were observed after 15 months. The frequency of probably benign assessments on screening US was 23.2% in our study, which was within the reported range of 8.6-41.4% (5, 6, 8, 12, 13) . The malignancy rate of 445 women with probably benign lesions was 0% at the first follow-up. Even when the three malignancies, which were newly developed lesions detected after 15 months, were included for analysis, the malignancy rate was very low, 0.7% (3/445), which was comparable with the 0-0.8% of previous reports (5, 6, 12) . In past reports with the inclusion of symptomatic probably benign lesions, the malignancy rates of probably benign lesions on US were 0.8-8.0%, which were higher than the 0-0.8% of the probably benign lesions on screening US (18, 20, 21) . Of the three cancers newly developed after 15 months, one cancer was a 3-mm ductal carcinoma in situ and two were 10-mm and 18-mm invasive ductal carcinomas without lymph node metastasis. The two invasive cancers were < 20 mm in size without any lymph node metastasis, and these cancers had similar lesion sizes and nodal statuses to those observed in cancers detected on screening US only (4) (5) (6) 8, 22) . Considering that the malignancy rate was actually 0% at the first follow-up, and that the cancers detected after 15 months were early stage cancers, short-term follow-up at six months for probably benign lesions on screening US does not seem to have benefits for cancer detection in women at average risk for breast cancer with dense beasts and negative or benign mammography results. In a recent study on screening US in women at average risk, follow-ups could be performed after 12 months after probably benign assessments (13) , which was comparable with our results. Also, annual follow-up has been considered in women with multiple bilateral circumscribed masses on screening US (14) .
The pretest probability is different between women at high risk and at average risk for breast cancer in screening settings (9, 12, 23) . Also, the pretest probability of women with concurrent breast cancers is different from that of women with negative or benign mammography. In women with synchronous breast cancer, 11.4% of probably benign lesions on US were malignant (9) . In a screening setting for women at high risk for breast cancer, 0.8% of probably benign lesions on US were malignant, which included probably benign lesions with concurrent category 4 or 5 findings and mammography and US were performed in a randomized order (4, 12) . The malignancy rates of probably benign lesions did decrease from 11.4% in a diagnostic setting to 0.8% in a screening setting (9, 12) . The pretest probability further decreased in women at average risk for breast cancer with negative or benign mammography results than in women at high risk. The malignancy rate of probably benign lesions in women at average risk was 0% at the first follow-up.
Of the 345 women in the six-month group, 63 had newly developed lesions only at the first follow-up, 18 at both the first and second follow-ups, and 34 only at the second follow-up. Twenty-nine of the 100 women in the 12 months group had newly developed lesions. New lesions appeared continuously on US at each follow-up and most of these lesions were probably benign lesions. These results were consistent with an earlier study, in which new probably benign lesions appeared consistently during the continuing follow-ups (12) . However, none of the newly developed probably benign lesions as well as the suspicious lesions was malignant. None of the four and two lesions with progression in the sixmonth and 12-month groups was malignant. In an era in which screening US is widely performed, radiologists can proactively try to reduce the recall rate and the number of percutaneous biopsies and surgical resections being performed (24) . The first follow-up at six months for probably benign lesions on screening US resulted in an increase in other unnecessary short-term follow-ups and benign biopsies without further detection of malignancy.
No medical organization recommends supplementary screening US based on breast density alone and currently legislation only recommends screening US for women with dense breasts regardless of breast cancer risk (25) . More women with dense breasts and at average risk for breast cancer have undergone screening US since the legislation for mandatory notification has gone into effect (1-3,26) . However, no direct evidence is available to justify the routine use of screening US in this population (23) . For screening US to be at least worth performing, false-positive results for the short-term follow-up rate and benign biopsy rate should be reduced. For multiple bilateral circumscribed masses on screening US, a follow-up at 12 months is recommended, like it is for lesions on mammography (14) . A benign assessment of category 2 is recommended for multiple non-simple cysts or complicated cysts 5 mm (6). A first follow-up at 12 months is recommended for probably benign lesions on screening US even in women at high risk because only one of six malignancies with probably benign lesions showed progression at the six-month follow-up (12) . In women at average risk, and with dense breasts and negative or benign mammography results, routine follow-up at 12 months can be sufficient for probably benign lesions on screening US.
There are some limitations to our study. First, our study was of retrospective design and 307 women without any follow-up at our institution and 68 with the first follow-up after 15 months were excluded. Thus, a selection bias might exist. One thing to note is that even when we recommended a follow-up at six months for all women with probably benign lesions, some patients did not come back for further follow-up and some came in after 15 months. However, as these situations also occur in daily practice, we believe our exclusion criteria will not affect our results significantly. Second, although seven different radiologists interpreted and performed mammography and US examinations, inter-observer variability was not evaluated. However, the malignancy rate of probably benign lesions in our institution has been reported to be <2% (18) .
In conclusion, a follow-up at 12 months can be considered for probably benign lesions on screening US in women at average risk for breast cancer with dense breasts. However, a large series prospective study is needed before clinical application.
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